Company description

ADPT, also known as Adaptive Biotechnologies Corporation, is a biotech company that specializes in developing innovative solutions for immune-driven diseases. Founded in 2009, the company utilizes its proprietary immune medicine platform to analyze and interpret massive amounts of genomic data to understand and decode the immune system. ADPT's advanced technology allows for the production of precise, individualized immunotherapies for diseases such as cancer, autoimmune disorders, and infectious diseases. With its headquarters in Seattle, Washington, ADPT has a global presence, with partnerships and collaborations with renowned institutions and companies worldwide. The company has a diverse portfolio of over 20 clinical-stage programs and has received FDA approval for its state-of-the-art diagnostic test, clonoSEQ, for detecting and monitoring minimal residual disease (MRD) in cancer patients. Additionally, ADPT has a strong financial standing, with growing revenues and collaborations with major pharmaceutical companies. With its cutting-edge technology and dedication to improving patient outcomes, ADPT continues to make significant strides in the field of precision medicine and is poised for continued success.